This website has been developed by Besins Healthcare (UK) Ltd.

This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) within the UK.

Please confirm that:

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.
  • Home
  • Testogel® (testosterone)

Testogel® (testosterone)

Why Testogel®?

Find out how you can help your patients get back to being themselves with Testogel® – information on dosing, administration, safety, efficacy and prescribing.1,2
Starting the conversation with your patients

Starting the conversation with your patients…

Advice and tools to support discussion with your patients as well as practical tips to facilitate application of Testogel® and support patient compliance.

References

  1. Testogel® 16.2 mg/g gel – Summary of Product Characteristics (SmPC) – https://www.medicines.org.uk/emc/product/8919/smpc. Accessed February 2022.
  2. Testogel® 40.5 mg, transdermal gel in sachet – Summary of Product Characteristics (SmPC) – https://www.medicines.org.uk/emc/product/13255/smpc. Accessed February 2022.

TES/2022/046. February 2023.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: pharmacovigilance@besins-healthcare.com